Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Both are with diet and exercise, respectively
Tirzepatide receptor pharmacology and predicted receptor occupancy GIPR-forward dual-incretin design, cAMP-biased GLP-1R with low beta-arrestin, GCGR negative control (EC50 329 nM)
Mounjaro is licensed for type 2 diabetes, and Wegovy is licensed for obesity/weight management
Others might negotiate directly with pharmaceutical companies for better pricing or even implement value-based purchasing agreements, where payments are tied to patient outcomes
US$ 20.61
US$ 29.69
US$ 23.18
US$ 29.15
